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THE physiological role of the pro-myelocytic leukae-
mia  (PML)  gene  product  is  poorly  defined.  Among
other functions,  PML  is involved  in haematopoietic
differentiation  and  in  control  of  cell  growth  and
tumorigenesis.  We  investigated  the  regulation  of
human PML expression by interferons (IFNs) and IL-1
in various human haematopoietic lines (U937, THP1,
HL60,  NB4),  in  human  diploid  fibroblasts  and  in
human  peripheral  blood  leukocytes.  Cytokine-
induced modulation of PML expression was assessed
by Northern blot analyses, flow cytometry studies and
in situ immunolabelling. Our data show that IFNs and
IL-1  upregulate  PML  transcript  and  protein  expres-
sion in a time and dose-dependent manner.  In  situ
immunolabelling revealed that upregulation of pro-
tein  expression  by  IFN-a is  a  consequence  of  a
marked increase in both the number and the inten-
sity of the staining of so-called PML nuclear bodies.
Our data suggest that stimulation of PML expression
by interferons and IL-1 may account for upregulation
of PML proteins observed in inflammatory tissues and
in proliferative states.
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Introduction
The PML (pro-myelocytic leukaemia) gene was identi-
fied originally as a fusion partner of the RARa gene in
the  chromosomal translocation  t(15;17)  specific  for
acute promyelocytic leukaemia (APL).
1–4 Several PML-
cDNAs have been isolated, resulting from alternative
RNA splicing in the 39 coding region of a single gene.
5
The  encoded  proteins  have  a  predicted  molecular
weight  ranging  from  47  to  98 kDa.  PML  proteins
belong  to  a  heterogeneous  family  of  DNA-binding
proteins characterized by the C3HC4 zinc binding ring
finger.  PML  protein  expression  features  a  typical
speckled nuclear pattern which is the consequence of
the  localization  of  the  protein  in  nuclear  compart-
ments  named  nuclear  bodies.
2 The  function  of  the
PML nuclear bodies is still unknown. Recently it has
been  shown  that  PML  participates  in  regulation  of
haematopoietic differentiation  and in control of cell
growth  and  tumorigenesis.
6 In  addition,  there  is
evidence that PML protein is aberrantly expressed in
a variety of pathological conditions including malig-
nancies.
7,8 The level of PML expression is upregulated
in  inflammatory tissues and in benign  or malignant
proliferative  states.
7–9 Cytokines,  especially  inter-
ferons  (IFNs),  are  likely  to  represent  some  of  the
mediators that may be involved in overexpression of
PML  under  these  circumstances.  Interferons  are
polypeptides  that  mediate  pleiotropic  effects  on
sensitive cells (reviewed in Sen and Lengyel
10). Major
activities  of  IFNs  include  immunomodulating  activ-
ities,  antiviral  effects  and  inhibition  of  cellular
growth. Two  families  of  IFNs  can  be  distinguished:
type I IFNs (IFN-a /b and IFN-v ) and type II IFN (g ).
Type I IFNs are encoded by a family of over 20 genes,
whereas  type  II  IFN  is  structurally  unrelated  and
encoded by a single gene.
10 An important function of
IFNs is regulation  of cellular growth of normal  and
malignant cells. The molecular mechanisms involved
in growth inhibition are poorly understood.
Here, we investigated modulation  of PML expres-
sion  by  interferons,  TNF-a and  IL-1.  We  present
evidence that  PML gene expression  is enhanced by
type I and type II interferons and by IL-1. We analysed
cytokine induced up-regulation of PML transcript and
protein  expression  in  human  haematopoietic  cell
lines,  in  human  diploid  fibroblasts  and  in  human
peripheral  blood  leukocytes.  Modulation  of  PML
protein  expression  by  IFN-a and  IL-1  was  assessed
with immunofluorescence flow cytometry. Immuno-
fluorescence in situ analysis of PML nuclear bodies
revealed that IFN treatment resulted in up-regulation
of both the intensity and the number of these nuclear
structures.
Materials and methods
Cell culture and materials
HL60, NB4, U937 and THP1 cells were obtained from
the American Type Culture Collection (Rockville, MD,
USA). Peripheral blood mononuclear cells (PBMNC)
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normal donors by Fioll-Hypaque (Lymphoprep, Nye-
gaard,  Norway)  density  separation  as  described.
11
Human  diploid  foreskin  fibroblasts  were  obtained
from the Department  of Dermatology, University  of
Mainz, Germany. All cells were grown in RPMI 1640
(Seromed,  Munich,  Germany)  supplemented  with
10%  fetal  calf  serum  (PAA,  C¨ olbe,  Germany),  pen-
icillin 50 IU/ml (Serva, Heidelberg, Germany), strepto-
mycin  50 IU/ml  (Serva),  sodiumpyruvate  1 nmol/l,
L-glutamine  2 mmol/l  (Seromed),  L-asparagine
20 m g/ml (Boehringer, Mannheim, Germany), 2-mer-
captoethanol  0.05 mmol/l,  HEPES  10mmol/l,  and
nonessential  aminoacids (Seromed) at  37°C and  5%
CO2 as described.
11
rh-IFN-a 2b with a specific activity of 1.8 3 10
8 IU/
mg was obtained from Essex Pharma  (Munich, Ger-
many). h-IFN-g was purchased from  Thomae (Biberach,
Germany). rh-IL-1a was kindly provided by Hoffmann
La Roche (Nutley, NJ), rh-TNF-a (6.6 3 10
6 IU/mg) by
Knoll AG (Ludwigshafen, Germany) and rh-IFN-b (3 3
10
8 IU/mg) by Bioferon (Laupheim, Germany).
Northern blot analysis
Total RNA was isolated by the method of Chomczyn-
ski  and  Sacchi
12 and  Northern  blot  analysis  was
performed  essentially  as  described.
11 RNA  (20 m g)
was subjected to electrophoresis on a 1% formalde-
hyde agarose gel and transferred to nylon membranes
(Hybond  N, Amersham Buchler, Braunschweig, Ger-
many). All hybridizations were carried out at 65°C for
16 h in a solution containing 1% BSA, 7% SDS, 1 mM
EDTA, and 0.5 M sodium phosphate buffer (pH 7.2).
Filters were hybridized with PML cDNA  insert radi-
olabelled by the random priming method. A  partial
cDNA probe for PML was synthesized by RT-PCR from
total  RNA  of  THP1  cells  using  primers  S1:
59 -ACCAGTCGGTGCGTGAGTT-39 and  AS1:
59 -TGGATCTCTGCGCTGATGTC-39 , corresponding to
nucleotides  525–544  and  715–734,  respectively  of
the  published  sequence.
13 This  part  of  the  PML
sequence is 100% homologous for all PML genes. The
synthesized cDNA was controlled by DNA-sequencing
and was subcloned into pCRTM II using a commercial
cloning kit (Invitrogen, Leek, Netherlands). For quan-
titative  analysis  of mRNA  levels  densitometric  scan-
ning  of  autoradiographs  was  applied  by  using  the
Quanti-scan® program. PML-specific transcript levels
were normalized to b -actin mRNA expression.
Immunofluorescence analysis
Quantitative  immunofluorescence  studies  of  PML
expression  were  performed  by  flow  cytometry
(EPICS,  Coulter,  Germany)  as  described
11 by  using
saturating  concentrations  of  a  PML  specific  mAb.
14
Normal mouse IgG (2 m g/ml) (Coulter, Krefeld, Ger-
many)  was  used  as  background  control,  and  FITC-
labelled  goat-anti-mouse  IgG  (Coulter,  Krefeld,  Ger-
many) as second reagent. A total of 50 000 cells was
analysed for each determination and specific fluores-
cence  intensity  was  calculated  on  the  basis  of
background fluorescence with control antibodies by
using the EPICS program. Mean specific fluorescence
intensity is given as channel number on a  log scale
from  1  to  1024  or  in  percentage  of  the  respective
untreated control.
Indirect immunofluorescence microscopy
Cells were air dryed overnight, fixed for 5 min with
aceton followed by incubation with PG-M3 antibody
14
as undiluted hybridoma supernatant  or with normal
mouse IgG (Coulter, Krefeld, Germany) at a concen-
tration of 2m g/ml for 5 min. Cells were then washed
with PBS and incubated with a FITC labelled goat-anti-
mouse  antibody  (Coulter,  Krefeld,  Germany)
(5 m g/ml).  Cells  were  analysed  with  a  fluorescence
microscope (Orthoplan, Leitz, Wetzlar, Germany).
Results
PML mRNA levels are upregulated by type I
and type II interferons
To investigate whether IFN affects PML gene expres-
sion,  we performed  Northern  blot  analyses  of total
cellular RNA extracted from various haematopoietic
cell lines cultured with and without IFNs. In all cell
types tested including the myeloid cell lines HL60 and
THP1, human diploid fibroblasts and human periph-
eral blood mononuclear cells a marked increase in the
three  major  PML  transcript  levels  was  observed  by
treatment  with  both  type  I  (a ,  b )  and  type  II  (g )
interferons  (Figs  1–4).  Dose  response  experiments
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FIG. 1. Induction of PML mRNA by interferon. Northern blot
analysis of PML-specific mRNA levels from IFN-treated and
untreated PBMNC. PBMNC were treated with the indicated
dose of IFN-a , IFN-b , TNF-a or LPS for 6h. Medium treated
PBMNC and freshly isolated PBMNC without further incuba-
tion were included as controls. Size fractionated total cellular
RNA  (20m g  per  lane)  was  blotted  and  hybridized  to  the
indicated 32P-labelled cDNA probes. For quantitative analysis
of mRNA levels densitometric scanning of autoradiographs
was applied as described in Materials and Methods.showed that upregulation  of PML mRNA levels was
already evident upon incubation with 30 IU/ml IFN-a
for 6 h (Fig. 1). At IFNa doses of 30 IU/ml and 3000 IU/
ml,  quantitative  analysis  employing  densitometric
scanning revealed a 3.2-fold and a 5.3-fold induction of
PML mRNA levels, respectively (Fig. 1). As a control,
PML transcript levels were monitored upon incubation
for  6 h  with TNF-a and  LPS  and  were  found  to  be
unchanged (Fig. 1). In experiments (Fig. 2 and data not
shown)  investigating  the  kinetics  of  IFN-a induced
PML  mRNA  upregulation  in  PBMNC,  maximum
enhancement  of  PML  transcript  expression  was
already observed upon incubation for 3 h (3000 IU/ml
IFN-a ). Thereafter PML transcript levels declined and
were  barely  visible  after  24 h  despite  continuous
incubation with 3000 IU/ml IFN-a (Fig. 2). In contrast
to IFN-a , IFN-b (3000 IU/ml) induced PML transcript
induction increased gradually over time and maximum
enhancement was reached at 24 h (Fig. 2). The time
course of IFN-g induced PML transcript enhancement
during a  6-h-incubation  period was similar  to IFN-a
(Fig. 3). Previous studies indicated that transcriptional
regulation of the PML gene is involved in up-regulation
of  PML  mRNA  by  IFNs.
15,16 To  confirm  that  IFN-
induced  modulation  of  PML  mRNA  is  independent
from  de  novo protein  synthesis,  we  performed
PML gene expression is upregulated by interferons and IL-1
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FIG. 2. Time-response of induction of PML mRNA by IFN-a and IFN-b . Northern blot analysis of PML-specific mRNA levels from
IFN-treated and untreated PBMNC. PBMNC were treated with the indicated dose of IFN-a and IFN-b for the indicated time.
Medium-treated PBMNC and freshly isolated PBMNC without further incubation were included as controls. Size fractionated
total cellular RNA (20m g per lane) was blotted and hybridized to the indicated 32P-labelled cDNA probes.
FIG. 3. Northern blot analysis of PML-specific mRNA levels
from IFN-a and IFN-g treated HL60 cells. HL60 cells were
treated with IFN-a (1000IU/ml) or IFN-g (1000U/ml) for the
indicated time or were left untreated. Northern blotting was
performed  as  described  above.  Densitometric  scanning
revealed  a  2.5-fold  and  1.9-fold  induction  of  PML-mRNA
levels upon incubation for 2h with IFN-a (1000IU/ml) and
IFN-g (1000IU/ml), respectively. Incubation for 6h with IFN-a
(1000IU/ml) and IFN-g (1000IU/ml) showed a 25.4-fold and a
27.4-fold induction of PML-specific transcript levels.
FIG. 4. Induction of PML-specific mRNA by IL-1a and IFN-a .
Human diploid foreskin fibroblasts were treated with IL-1a
(100IU/ml), with IFN-a (1000IU/ml) or with a combination of
IFN-a (1000IU/ml) and IL-1a (100IU/ml) for 6h. Cells were
grown in the absence or presence of an inhibitor of protein
tyrosine kinases (genistein 50m g/ml). Northern blotting was
performed  as  described  above.  For  quantitative  analysis,
PML-specific  transcript  levels  were  analysed  by  densito-
metric scanning and normalized to b -actin mRNA expression
as described in Materials and Methods.Northern blot analyses with and without an inhibitor
of protein synthesis (CHX). These experiments demon-
strated  that  CHX  had  no  effect  on  IFN-induced
upregulation of PML mRNA (data not shown).
The influence of IL-1a on  PML transcript expres-
sion  was  investigated  in  human  foreskin  fibroblasts
(Fig. 4). Treatment with IL-1a at a dose of 100 IU/ml
for  6 h  resulted  in  a  3.8-fold  upregulation  of  PML-
specific  mRNA  levels  as  analysed  by  densitometric
scanning. A more pronounced enhancement of PML
transcript  levels  (7.1-fold  induction)  was  observed
when  cells  were  incubated  with  IFN-a .  IL-1  in
combination  with  IFN-a stimulated  PML  mRNA
expression to more than twice the level obtained with
IFN-a alone (15.3 fold induction relative to medium
control), as estimated by densitometric scanning. Co-
incubation with genistein,
17 an inhibitor of tyrosine
kinases,  significantly  inhibited  the  IFN-induced
increase in the level of PML transcripts, whereas no
effect  of  genistein  on  IL-1  induced  PML  mRNA
expression  was  noted  (Fig.  4).  Similar  results  were
obtained using the amnion fibroblast cell line WISH
(data not shown).
Influence of IFN-a on PML protein expression
In  an  attempt  to  investigate  modulation  of  PLM
protein  expression,  we  performed  flow  cytometry
analyses.  IFN-a treatment  of  the  three  myeloid  cell
lines HL60, NB4 and U937 resulted in upregulation of
PML protein expression. For example, in HL60 cells,
upregulation of PML expression was detectable upon
incubation  with  IFN-a for  18 h  (Fig.  5). The  time
course of IFN-induced enhancement of PML protein
expression  was  monitored  in  U937  cells  (Fig.  6).
Induction of PML was not detectable upon incubation
with  IFN-a (1000IU/ml)  for  only  6 h  or  12 h  but
started thereafter and reached a plateau at 20 h (Fig. 6
and data not shown). Dose–response experiments in
U937 cells revealed that incubation with 10U/ml IFN-
a for 20 h already  resulted in slight upregulation  of
PML  protein  expression  to  113%  of  the  untreated
control  (Fig.  7).  Maximum  upregulation  of  PML
expression  to  160%  of  that  of  untreated  cells  was
achieved  by  incubation  with  doses  greater  than
500 IU/ml IFN-a (Fig. 7). These data indicate that half-
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FIG. 5. Induction of PML protein by IFN-a in HL60 cells. HL60
cells were treated with (B) and without (A) IFN-a (1000IU/ml)
for 18h. Expression of PML protein was analysed by flow
cytometry using a specific monoclonal anti-PML antibody as
descibed in Materials and Methods. Normal mouse IgG was
used as isotype control.
FIG. 6. Kinetics of induction of PML protein by IFN-a in U937
cells.  U937  cells  were  treated  with  and  without  IFN-a
(1000IU/ml) for the indicated time (A: medium control; B:
IFN-a for 19.5h). Induction of PML protein was monitored by
flow cytometry using a specific monoclonal antibody recog-
nizing the aminoterminal  domain of PML as described in
Materials and  Methods.  Normal  mouse IgG was  used as
isotype control. Given is the mean log specific fluorescence
intensity as described in Materials and Methods.
FIG. 7. Dose-response of induction of PML protein by IFN-a in
U937 cells. U937 cells were incubated for 18h in the absence
or presence of the indicated dose of IFN-a and PML protein
expression was analysed by flow cytometry using a specific
monoclonal  antibody as described in Materials and Meth-
ods. Given is the mean log specific fluorescence intensity as
described in Materials and Methods.maximum IFN-a response is reached at 50 U/ml IFN-a
which corresponds to the IFN-a concentration nee-
ded  to  achieve  a  half-maximum  response  in  other
biological activities of IFN-a .
10
When  human  foreskin  fibroblasts  were  grown  in
the  absence  or  or  in  the  presence  of  saturating
concentrations of IL-1a , a nearly two-fold increase of
PML protein expression was detected by flow cyto-
metry analysis (Table 1). A similar result was obtained
upon incubation with IFN-a (100 IU/ml). The combi-
nation  of  IL-1  and  IFN-a stimulated  PML  protein
expression to about three times the level observed in
untreated controls (Table 1).
Analysis of PML nuclear bodies
Since it has been shown that PML proteins are located
within  subnuclear  structures  from  active  sites  of
transcription and splicing, the so-called PML nuclear
bodies were monitored during IFN-a treatment using
indirect  immunofluorescence  staining.  PML-specific
immunofluorescence varied in intensity between the
cell lines tested. In all cell lines tested (NB4, HL60,
U937)  and  in  peripheral  blood  leukocytes  the  con-
stitutive levels of endogenous proteins were detect-
able  (Figs  8  and  9).  Peripheral  blood  leukocytes
revealed  specific  immunolabelling  of  PML  nuclear
bodies in neutrophils and monocytes (Fig. 8). When
HL60  and  U937  cells were incubated for  15h with
and  without  IFN-a (1000 U/ml)  a  marked  enhance-
ment of the immunolabelling was observed in treated
cells.  Both  the  intensity  of  the  staining  and  the
number  of  the  labelled  PML  nuclear  bodies  was
increased significantly (Fig. 9 and data not shown).
Discussion
Our data confirm and extend previous studies demon-
strating that cytokines are involved in modulation of
PML  gene  expression.
15,16 We  show  that  PML  tran-
scripts  rapidly  accumulate  upon  treatment  with
interferons  in  a  variety  of  haematopoietic cell  lines
and  in  primary  diploid  cells.  However,  our  experi-
ments demonstrate a marked difference in the time
course of PML-mRNA induction  between  IFN-a and
IFN-b .  Induction  of  PML  in  response  to  IFN  was
shown  to  be  independent  from  de  novo protein
synthesis  and  actinomycin  sensitive  indicating  that
PML mRNA levels are transcriptionally  regulated by
IFNs.
16 Recently, evidence has been provided that the
PML  gene  is  transcriptionally  upregulated  by  IFNs
through activation and binding  of STATs to an ISRE
and a GAS element in the untranslated first exon.
18
IFNs activate STATS through tyrosine phosphorylation
by members of the JAK tyrosine kinase family.
19 Our
results demonstrating inhibition of IFN-induced upre-
gulation  of  PML  transcripts  by  the  tyrosine  kinase
inhibitor genistein are consistent with these findings.
Flow cytometry analyses using a specific monoclonal
anti-PML  antibody  recognizing  the  aminoterminal
domain  clearly  demonstrate  that  IFNs  induce  PML
PML gene expression is upregulated by interferons and IL-1
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Table  1.  Induction  of  PML  protein  by  IFN-a ,  IL-1a or  a
combination of both in human diploid fibroblasts
Treatment D
Mean X
x-fold
induction
Medium 1.29 1.0
IFN-a (100IU/ml) 2.75 2.1
IL-1a (100IU/ml) 2.31 1.8
IL-1a (1000IU/ml) 2.43 1.9
IFN-a (100IU/ml) + IL-1a (100IU/ml) 4.30 3.3
IFN-a (100IU/ml) + IL-1a (1000IU/ml) 3.80 3.0
Fibroblasts were incubated with and without the indicated cytokines
at the indicated dose for 21.5h. Induction of PML protein expression
was analysed  by flow cytometry using a specific anti-PML mono-
clonal mouse antibody and normal mouse IgG as control as described
above.  Given  is  the  mean  log  specific  fluorescence  intensity  as
described in Materials and Methods.
FIG.  8.  In situ immunofluorescence  analysis  of  PML  proteins  in  human  peripheral  blood  leukocytes.  Indirect immuno-
fluorescence analysis of a peripheral blood smear was performed using the specific mouse monoclonal antibody PG-M3 (B)
and normal mouse IgG (A) as control as described in Materials and Methods. Specific immunolabelling can be detected in
neutrophils and monocytes which were identified by morphologic criteria.
(A) (B)protein in a dose dependent manner. Recently, it has
been  shown  that  PML  protein  expression  has  a
speckled nuclear pattern.
15 This is due to localization
of  the  protein  in  poorly  defined  nuclear  organelles
named nuclear bodies. The functions of the nuclear
bodies  are  unknown  except  for  the  coiled  bodies
which  act  as  storage  compartments  for  splicing
factors.
20 To  analyse  expression  of  PML  proteins
within nuclear bodies we performed indirect in situ
immunofluorescence  studies.  In  situ immunolabel-
ling  of  PML  protein  expression  revealed  an  IFN-
induced increase in number and intensity of so-called
PML nuclear bodies.
To the best of our knowledge induction of PML by
IL-1 has not been described so far. Here we show that
IL-1a rapidly  induces  PML  mRNA  expression  in
fibroblasts. Since IL-1 is a potent inducer of IFN-a and
IFN-b
21 it could be argued that the observed induc-
tion of PML mRNA expression is a consequence of IL-
1  induced autocrine production  of interferon-b . We
addressed this issue by employing the tyrosine kinase
inhibitor genistein. Genistein was shown to strongly
inhibit  IFN  signalling.
17 Our  experiments  clearly
show  that  in  fibroblasts  genistein  is  not  able  to
suppress  the  IL-1  induced  upregulation  of  PML
transcripts,  whereas  IFN-induced  enhancement  of
PML-specific transcripts was strongly inhibited. Thus,
indirect regulation of PML by IL-1 induced autocrine
production of IFN-b appears unlikely. Flow cytometry
analysis revealed that IL-1 and IFN-a act synergistically
in induction of PML proteins. This regulation could be
involved  in  the  observed  upregulation  of  PML  pro-
teins in inflammation. In contrast to normal tissues, in
inflammatory  tissues  the  level  of  PML  proteins  is
upregulated.
7,8 Local  production  of  IL-1  has  been
demonstrated in inflammatory and autoimmune dis-
ease and  this  may contribute  to tissue  damage  and
repair.
21,22 In fibroblasts, IL-1  mediates tissue repair
after  inflammation  and  injury  by  regulating  key
proteins necessary for formation of the extracellular
matrix.
21,22 The data presented here suggest that IL-1
induced PML expression may represent the molecular
basis for the observed upregulation of PML proteins
during  inflammation.  IFNs,  as  part  of  the  cytokine
network are indirectly induced by regulators such as
tumour necrosis factor during immune responses and
inflammation. This may contribute to upregulation of
PML in inflammatory tissues by synergistic action of
IFN-a and IL-1 in enhancing PML protein expression
in fibroblasts.
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FIG. 9. In situ immunofluorescence analysis of PLM proteins in HL60 cells. HL60 cells were incubated with (C, D) and without
(A, B) IFN-a (1000IU/ml) for 15h. Indirect immunofluorescence analysis was performed using the specific mouse monoclonal
antibody PG-M3 (B, D) and normal mouse IgG (A, C) as control as described in Materials and Methods.
(A) (B)
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